Evidence map›Paper›PMID 19621241›Full record

ArticleVirchows Archiv : an international journal of pathology2009

The distribution of lesions in 1-14-mm invasive breast carcinomas and its relation to metastatic potential.

Tibor Tot, Gyula Pekár, Syster Hofmeyer, Thomas Sollie, Mária Gere, Miklós Tarján

Abstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Tibor TotDepartment of Pathology and Clinical Cytology, Central Hospital Falun, Falun, Sweden. tibor.tot@ltdalarna.se
Gyula Pekár
Syster Hofmeyer
Thomas Sollie
Mária Gere
Miklós Tarján
Falun Hospital · SEÖrebro University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We analyzed 301 consecutive cases of 1-14-mm invasive breast carcinomas documented in large-format histological sections to determine the distribution of invasive and in situ foci. We also aimed to determine whether this distribution was related to the frequency of demonstrable vascular invasion and lymph node metastases. One third of the carcinomas (31.9%, 96 cases) had a multifocal invasive component and a more than doubled relative risk of vascular invasion (RR = 2.3642, 95% confidence interval (CI) = 1.5077-3.7073) and lymph node metastasis (RR = 2.7760, 95% CI = 1.6337-4.7171) compared to unifocal invasive carcinomas. Invasive carcinomas with diffuse in situ component had an elevated relative risk for vascular invasion (RR = 2.2201, 95% CI = 1.4049-3.5083) and lymph node metastasis (RR = 1.9201, 95% CI = 1.1278-3.2691) compared to those with unifocal or multifocal in situ lesions. However, multifocality of the invasive component was associated with a substantially elevated risk of vascular invasion and lymph node metastasis, even in cases with diffuse in situ component. Similar observations were made in the 1-9- and 10-14-mm invasive carcinoma subgroups. These findings indicate that lesion distribution has prognostic relevance for 1-14-mm invasive breast carcinomas and underline the importance of using special techniques in breast pathology for proper assessment of this parameter.

Indexed as

Breast NeoplasmsCarcinoma, Ductal, BreastFemaleHumansLymphatic MetastasisNeoplasm InvasivenessNeoplasm MetastasisNeovascularization, PathologicPrognosisRetrospective Studies

Identifiers

PMID19621241
OpenAlexW2055648367

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.